ArticleInternational journal of cancer2007
Racial differences in clinical and pathological associations with PhIP-DNA adducts in prostate.
Article in International journal of cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Xenobiotic metabolizing gene variants, dietary heterocyclic amine intake, and risk of prostate cancer.Cancer research · 2009Trial
- Exploring experimental models of prostate cancer in chemoprevention: Oxidative stress as a key pathway to translational research.Pathology international · 2025Review
- The Cooked Meat Carcinogen 2-Amino-1-methyl-6-phenylimidazo[4,5-Chemical research in toxicology · 2022Review
- Metabolism and biomarkers of heterocyclic aromatic amines in humans.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2021Review
- DNA adducts: Formation, biological effects, and new biospecimens for mass spectrometric measurements in humans.Mass spectrometry reviews · 2020Review
- Dietary Carcinogens and DNA Adducts in Prostate Cancer.Advances in experimental medicine and biology · 2019Review
- Biomonitoring DNA Adducts of Cooked Meat Carcinogens in Human Prostate by Nano Liquid Chromatography-High Resolution Tandem Mass Spectrometry: Identification of 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine DNA Adduct.Analytical chemistry · 2016Article
- The diet as a cause of human prostate cancer.Cancer treatment and research · 2014Review
- 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-DNA adducts in benign prostate and subsequent risk for prostate cancer.International journal of cancer · 2013Article
- Neighborhood socioeconomic status modifies the association between individual smoking status and PAH-DNA adduct levels in prostate tissue.Environmental and molecular mutagenesis · 2012Article
- Red wine consumption is inversely associated with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-DNA adduct levels in prostate.Cancer prevention research (Philadelphia, Pa.) · 2011Article
- Polymorphisms in hOGG1 and XRCC1 and risk of prostate cancer: effects modified by plasma antioxidants.Urology · 2010Article
- Well-done meat intake, heterocyclic amine exposure, and cancer risk.Nutrition and cancer · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
African-American men have a higher dietary intake of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), which is the most abundant heterocyclic amine in cooked meats and is carcinogenic in rat prostate through the formation of DNA adducts. To determine the clinical and demographic factors associated with PhIP-DNA adduct levels, the biologically effective dose of PhIP in human prostate, we immunohistochemically measured PhIP-DNA adducts in a study of 162 Caucasian and 102 African-American men who underwent radical prostatectomy for prostate cancer. A strong correlation between PhIP-DNA adduct levels in prostate tumor and adjacent non-tumor cells was observed (rho = 0.62; p < 0.0001); however, non-tumor cells had significantly higher adduct levels compared with tumor (0.167 optical density (OD) units +/- 0.043 vs. 0.104 OD +/- 0.027; p < 0.0001). Race was not associated with PhIP-DNA adduct levels in either tumor or non-tumor cells, but race-specific associations were observed. In prostate tumor and non-tumor cells, tumor volume had the strongest association with PhIP-DNA adducts in Caucasians, whereas in African-Americans prostate volume was most strongly associated with adduct levels in tumor cells and advanced Gleason grade had the strongest association in non-tumor cells. In race interaction models, while the only statistically significant interaction was between African-American race and advanced Gleason grade in non-tumor cells (beta = 0.029; p = 0.02), in tumor cells we observed opposite effects by race (positive for African-Americans, negative for Caucasians) for older age and high PSA levels at diagnosis. In conclusion, while PhIP-DNA adduct levels in prostate cells do not vary significantly by race, our results suggest that PhIP exposure may have stronger effects on prostate tumor differentiation in African-American men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.